Related references
Note: Only part of the references are listed.Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders
Anna S. Lok et al.
JOURNAL OF HEPATOLOGY (2014)
Combinations of Lambda Interferon with Direct-Acting Antiviral Agents Are Highly Efficient in Suppressing Hepatitis C Virus Replication
Jacques Friborg et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C
Jean-Pierre Bronowicki et al.
ANTIVIRAL THERAPY (2013)
INTERIM ANALYSIS OF AN INTERFERON (IFN)- AND RIBAVIRIN (RBV)-FREE REGIMEN OF DACLATASVIR (DCV), ASUNAPREVIR (ASV), AND BMS-791325 IN TREATMENT-NAIVE, HEPATITIS C VIRUS GENOTYPE 1-INFECTED PATIENTS
G. T. Everson et al.
JOURNAL OF HEPATOLOGY (2013)
DACLATASVIR COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN FOR 12 OR 16 WEEKS IN PATIENTS WITH HCV GENOTYPE 2 OR 3 INFECTION: COMMAND GT2/3 STUDY
G. J. Dore et al.
JOURNAL OF HEPATOLOGY (2013)
EXPOSURE-RESPONSE ANALYSES OF ASUNAPREVIR IN COMBINATION WITH DACLATASVIR ± PEGINTERFERON/RIBAVIRIN AMONG PATIENTS WITH GENOTYPE 1 CHRONIC HCV INFECTION: DOSE SELECTION FOR PHASE 3 CLINICAL TRIALS
P. Chan et al.
JOURNAL OF HEPATOLOGY (2013)
Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options
Yoshiyuki Suzuki et al.
JOURNAL OF HEPATOLOGY (2013)
Pharmacokinetics of the NS3 Protease Inhibitor, Asunaprevir (ASV, BMS-650032), in Phase I Studies in Subjects With or Without Chronic Hepatitis C
Timothy Eley et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2013)
Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)
Fiona McPhee et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Single- and Multiple-Ascending-Dose Studies of the NS3 Protease Inhibitor Asunaprevir in Subjects with or without Chronic Hepatitis C
Claudio Pasquinelli et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Effect on Hepatitis C Virus Replication of Combinations of Direct-Acting Antivirals, Including NS5A Inhibitor Daclatasvir
Lenore A. Pelosi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders
Kazuaki Chayama et al.
HEPATOLOGY (2012)
CONFIRMATION THAT QUADRUPLE THERAPY WITH DACLATASVIR (NS5A INHIBITOR), ASUNAPREVIR (NS3 INHIBITOR) AND PEGINTERFERON/RIBAVIRIN RESULTS IN HIGH RATE OF SVR4 IN HCV GENOTYPE 1 NULL RESPONDERS
A. Lok et al.
JOURNAL OF HEPATOLOGY (2012)
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial
Stanislas Pol et al.
LANCET INFECTIOUS DISEASES (2012)
Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation
Robert J. Fontana et al.
LIVER TRANSPLANTATION (2012)
Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
Anna S. Lok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Telaprevir, Boceprevir, Cytochrome P450 and Immunosuppressive Agents - A Potentially Lethal Cocktail
Michael Charlton
HEPATOLOGY (2011)
Multiple Ascending Dose Study of BMS-790052, a Nonstructural Protein 5A Replication Complex Inhibitor, in Patients Infected with Hepatitis C Virus Genotype 1
Richard E. Nettles et al.
HEPATOLOGY (2011)
BMS-650032, AN NS3 INHIBITOR, IN COMBINATION WITH PEGINTERFERON ALPHA-2A AND RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION
J. -P. Bronowicki et al.
JOURNAL OF HEPATOLOGY (2011)
Predicting Drug Disposition via Application of a Biopharmaceutics Drug Disposition Classification System
Leslie Z. Benet
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2010)
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Min Gao et al.
NATURE (2010)
Share Paper
